Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– – Combination ...

Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today is providing a number of strategic updates, including its recently executed option agreement with Incyte ...

Significant transformations are on the horizon for the school education framework in India. A revised syllabus for students ...

Caltrans said its project will rehabilitate the roadway, minimize the need for future maintenance and add a series of road ...